• By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
OK
Advertisement
In the last half-hour
In the last 2 hours
In the last 4 hours
In the last 6 hours
In the last 8 hours
Earlier today
Yesterday
Scientists find first drug to treat sleep apnea Knowridge Science Report11:40 23-Jun-24
In the last 7 days
Weight-loss drug effective in treating apnea, study finds The Tribune, California21:42 21-Jun-24
Study Identifies First Drug Therapy for Sleep Apnea UC San Diego News Center20:51 21-Jun-24
WHO, Lilly warn of fake weight-loss drugs Miami Herald20:28 21-Jun-24
In the last month
Weight Loss Drugs Weigh Heavy on Employer Health Plans Business Wire (Press Release)14:09 6-Jun-24
view more headlines
24 Jun 17:29

About our Tirzepatide (Mounjaro, Zepbound) news

Latest news on tirzepatide (Mounjaro, Zepbound), the groundbreaking diabetes and obesity drug making headlines for its impressive clinical results and potential to revolutionise weight management. Tirzepatide was approved for treatment of diabetes in the United States in May 2022, in the European Union in September 2022, in Canada in November 2022, and in Australia in December 2022.

Tirzepatide, developed by Eli Lilly and Company, is a novel dual GIP and GLP-1 receptor agonist that has shown remarkable efficacy in clinical trials for type 2 diabetes, obesity, and related metabolic conditions. Marketed under the brand names Mounjaro and Zepbound, this injectable medication has garnered significant attention from the medical community, patients, and investors alike. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Stay informed about the latest developments surrounding tirzepatide, including updates on its clinical trials, regulatory approvals, and real-world patient experiences. Our feed covers the drug's impressive weight loss results, with some participants losing up to 20% of their body weight, as well as its ability to improve blood sugar control and cardiovascular health markers in people with type 2 diabetes. Tirzepatide was approved by the FDA for weight loss in November 2023, under the brand name Zepbound.

As tirzepatide gains traction, our feed also explores the broader implications of this innovative treatment, such as its potential impact on the global obesity epidemic and the future of diabetes management. We delve into the science behind the drug's unique dual-targeting mechanism and its advantages over existing GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy).

In addition to the medical aspects, our tirzepatide feed covers the business and financial news surrounding the drug, including Eli Lilly's stock performance, market projections, and the competitive landscape of the obesity and diabetes treatment market. We also report on any potential challenges or controversies associated with the drug, such as access issues, cost concerns, or side effects.

As the buzz around tirzepatide continues to grow, our feed keeps you updated on the cultural and societal impact of this groundbreaking medication. We explore patient stories, expert opinions, and the evolving discourse around weight loss drugs and their role in addressing the complex issues of obesity and metabolic health. In November 2023, the UK Medicines and Healthcare products Regulatory Agency revised the indication for tirzepatide to include treatment for weight loss.

Our NewsNow feed on tirzepatide (Mounjaro, Zepbound) is your go-to source for comprehensive, up-to-date information on this remarkable drug and its transformative potential in the fields of diabetes, obesity, and metabolic health. Stay informed with the latest news, insights, and analysis from reliable sources as tirzepatide continues to make waves in the medical world and beyond.


Publication filters

Headline Density

Sorry, no headlines or news topics were found. Please try different keywords.